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abstract
Influenza A is a serious disease that causes significant morbidity and mortality, and
vaccines against the seasonal influenza disease are of variable effectiveness. In this
paper, we discuss use of the pepitope method to predict the dominant influenza strain
and the expected vaccine effectiveness in the coming flu season. We illustrate how
the effectiveness of the 2014/2015 A/Texas/50/2012 [clade 3C.1] vaccine against the
A/California/02/2014 [clade 3C.3a] strain that emerged in the population can be es-
timated via pepitope. In addition, we show by a multidimensional scaling analysis of
data collected through 2014, the emergence of a new A/New Mexico/11/2014-like clus-
ter [clade 3C.2a] that is immunologically distinct from the A/California/02/2014-like
strains.
Author Summary
We show that the pepitope measure of antigenic distance is correlated with influenza A
H3N2 vaccine effectiveness in humans with R2 = 0.75 in the years 1971–2015. As
an example, we use this measure to predict from sequence data prior to 2014 the ef-
fectiveness of the 2014/2015 influenza vaccine against the A/California/02/2014 strain
that emerged in 2014/2015. Additionally, we use this measure along with a reconstruc-
tion of the probability density of the virus in sequence space from sequence data prior
to 2015 to predict that a newly emerging A/New Mexico/11/2014 cluster will likely be
the dominant circulating strain in 2015/2016.
Introduction
Influenza is a highly contagious virus, usually spread by droplet or fomite transmission.
The high mutation and reassortment rates of this virus lead to significant viral diversity
in the population [1, 2]. In most years, one type of influenza predominates among
infected people, typically A/H1N1, A/H3N2, or B. In the 2014/2015 season, A/H3N2
was the most common [3]. While there are many strains of influenza A/H3N2, typically
there is a dominant cluster of strains that infect most people during one winter season.
Global travel by infected individuals leads this cluster of sequences to dominate in most
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affected countries in a single influenza season. New clusters arise every 3–5 years by
the combined effects of mutation and selection [4, 5]. There is significant selection
pressure upon the virus to evolve due to prior vaccination or exposure [6, 7].
Due to evolution of the influenza virus, the strains selected by the World Health
Organization (WHO) for inclusion in the seasonal vaccine are reviewed annually and
often updated. The selection is based on which strains are circulating, the geographic
spread of circulating strains, and the expected effectiveness of the current vaccine
strains against newly identified strains [8]. There are to date 143 national influenza
centers located in 113 countries that provide and study influenza surveillance data.
Five WHO Collaborating Centers for Reference and Research on Influenza (Centers
for Disease Control and Prevention in Atlanta, Georgia, USA; National Institute for
Medical Research in London, United Kingdom; Victorian Infectious Diseases Ref-
erence Laboratory in Melbourne, Australia; National Institute of Infectious Diseases
in Tokyo, Japan; and Chinese Center for Disease Control and Prevention in Beijing,
China) are sent samples for additional analysis. These surveillance data are used to
make forecasts about which strains are mostly likely to dominate in the human popu-
lation. These forecasts are used by the WHO to make specific recommendations about
the strains to include in the annual vaccine, in 2016 one each of a A/H1N1, A/H3N2,
and influenza B Yamagata lineage or Victoria lineage subtype strain. Additionally, for
each recommended strain there is often a list of 5–6 “like” strains that may be substi-
tuted by manufacturers for the recommended strain and which may grow more readily
in the vaccine manufacturing process that uses hen’s eggs.
We here focus on predicting the expected effectiveness of the current vaccine strains
against newly identified strains and on predicting or detecting the emergence of new
influenza strains. Predicting effectiveness or emergence without recourse to animal
models or human data is challenging. The influenza vaccine protects against strains
similar to the vaccine, but not against strains sufficiently dissimilar. For example, the
A/Texas/50/2012(H3N2) 2014/2015 Northern hemisphere vaccine has been observed
to not protect against the A/California/02/2014(H3N2) virus. Furthermore, there is
no vaccine that provides long-lasting, universal protection, although this is an active
research topic [9].
Vaccine effectiveness is expected to be a function of “antigenic distance.” While
antigenic distance is often estimated from ferret animal model hemagglutination inhi-
bition (HI) studies, the concept is more general. In particular, in the present study we
are interested in the antigenic distance that the human immune system detects. A mea-
surement of antigenic distance that is predictive of vaccine effectiveness for H3N2 and
H1N1 influenza A in humans is pepitope [10–14]. The quantity pepitope is the fraction
of amino acids in the dominant epitope region of hemagglutinin that differ between the
vaccine and virus [11]. The structure of the H3N2 hemagglutinin is shown in Figure 1,
and the five epitopes are highlighted in color. The quantity pepitope is an accurate esti-
mate of influenza antigenic distance in humans. Previous work has shown that pepitope
correlates with influenza H3N2 vaccine effectiveness in humans with R2 = 0.81 for
the years 1971–2004 [11]. While our focus here is H3N2, other work has shown that
pepitope also correlates with influenza H1N1 vaccine effectiveness in humans [13, 15].
The pepitope measure has been extended to the highly pathogenic avian influenza H5N1
viruses [16]. The pepitope measure has additionally been extended to veterinary appli-
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cations, for example equine H3N8 vaccines [17].
In order to determine the strains to be included in the vaccine, the emergence of
new strains likely to dominate in the human population must be detected. We here use
the method of multidimensional scaling to detect emerging strains. As an example, we
apply the approach to the 2014–2015 season. Dominant, circulating strains of influenza
H3N2 in the human population typically have been present at low frequencies for 2–3
years before fixing in the population. While the frequencies of such emerging strains
are low, they are high enough that samples are collected, sequenced, and deposited in
GenBank. Multidimensional scaling, also known as principal component analysis [18],
has been used to identify clusters of influenza from animal model data [4]. Thus,
this method can be used to detect an incipient dominant strain for an upcoming flu
season from sequence data alone, before the strain becomes dominant [5]. We here use
this method to detect emerging strains in the 2014–2015 season. Interestingly, H3N2
evolves such that the reconstructed phylogenetic tree has a distinct one-dimensional
backbone [5, 19].
In this paper, we show that the current A/Texas/50/2012 vaccine is predicted not to
protect against the A/California/02/2014 strain that has emerged in the population, con-
sistent with recent observations [20]. This A/California/02/2014 strain can be detected
and predicted as a transition from the A/Texas/50/2012 strain. The proposed summer
2015 vaccine strain is A/Switzerland/9715293/2013, which is identical in the expressed
hemagglutinin (HA1) region to the A/California/02/2014 strain [21]. Furthermore, we
find that there is in 2015/2016 a transition underway from the A/California/02/2014
cluster to an A/New Mexico/11/2014 cluster. The latter may be an appropriate vaccine
component for next season, because the new A/New Mexico/11/14 cluster is emerging
and appears based upon representation in the sequence database to be displacing the
A/California/02/14 cluster.
Methods
The pepitope method
We calculate pepitope, the fraction of amino acids in the dominant epitope region of
hemagglutinin that differ between the vaccine and virus [11]. We use epitope sites as
in [11] and illustrated in Fig. 2. For each of the five epitopes [10, 11], we calculate
the number of amino acid substitutions between the vaccine and virus and divide this
quantity by the number of amino acids in the epitope. The value of pepitope is defined
to be the largest of these five values.
Identification of Vaccine Strains and Circulating Strains
The dominant circulating influenza H3N2 strain and the vaccine strain were determined
from annual WHO reports [20, 22–33]. These strains are listed in Table 1. In many
years, the WHO report lists a preferred vaccine strain, while the actual vaccine is a
“like” strain. Additionally, in some years, different vaccines were used in different
regions. For each study listed in Table 1, the vaccine strain used is listed.
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Estimation of Vaccine Effectiveness
Vaccine effectiveness can be quantified. It is defined as [11]
E =
u− v
u
(1)
where u is the rate at which unvaccinated people are infected with influenza, and v is
the rate at which vaccinated people are infected with influenza.
The vaccine effectiveness in Eq. 1 was calculated from rates of infection observed
in epidemiological studies. Influenza H3N2 vaccine effectiveness values for years
1971–2004 are from studies previously collected [11]. Laboratory-Confirmed data
for the years 2004–2015 were collected from the studies cited in Table 1. Epidemi-
ological data from healthy adults, aged approximately 18–65, were used. For each
study, the total number of unvaccinated subjects, Nu, the total number of vaccinated
subjects, Nv , the number of H3N2 influenza cases among the unvaccinated subjects,
nu, and the number of H3N2 influenza cases among the vaccinated subjects, nv , are
known and listed in the table. From these numbers, vaccine effectiveness was calcu-
lated from Eq. 1, where u = nu/Nu and v = nv/Nv . Error bars, ε, on the calculated
effectiveness values were obtained assuming binomial statistics for each data set [11]:
ε2 = [σ2v/u
2/Nv + (v/u
2)2σ2u/Nu], where σ
2
v = v(1− v), and σ2u = u(1− u).
Virus Sequence Data in 2013 and 2014
The evolution of the HA1 region of the H3N2 virus in the 2013/2014 and 2014/2015
seasons was analyzed in detail. We downloaded from GenBank the 1006 human HA1
H3N2 sequences that were collected in 2013 and the 179 human HA1 H3N2 sequences
that were collected in 2014.
Sequence Data Alignment
All sequences were aligned before further processing by multialignment using Clustal
Omega. Only full length HA1 sequences of 327 amino acids were used, as partial
sequences were excluded in the GenBank search criterion. Default clustering parame-
ters in Clustal Omega were used. There were no gaps or deletions detected by Clustal
Omega in the 2013 and 2014 sequence data.
Multidimensional Scaling
Multidimensional scaling finds a reduced number of dimensions, n, that best reproduce
the distances between all pairs of a set of points. In the present application, the points
are HA1 sequences of length 327 amino acids, and the data were reduced to n = 2
dimensions. Distances between two sequences were defined as the Hamming distance,
i.e. the number of differing amino acids, divided by the total length of 327. In this way,
multidimensional scaling places the virus sequences in a reduced sequence space so
that distances between pairs of viral sequences are maintained as accurately as possible.
This low-dimensional clustering method enables one to visualize the viruses, by finding
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the two best dimensions to approximate the Hamming distances between all clustered
sequences.
Gaussian Kernel Density Estimation
The method of Gaussian kernel density estimation was used to predict the probabil-
ity density of sequences in the reduced sequence space identified by multidimensional
scaling [5]. Briefly, each sequence was represented by a Gaussian distribution cen-
tered at the position where the sequence lies in the reduced space. The total esti-
mated viral probability density was the sum of all of these Gaussians for each virus
sequence. The weight of the Gaussian for each sequence was constant. The stan-
dard deviation of the Gaussian for each sequence was specified as either one-half,
one, or three substitutions in the dominant epitope of the virus, as discussed later.
In other words, the reconstructed probability density of the viruses in the reduced
(x, y) space, as estimated by the sequences from GenBank, was given by p(x, y) ∝∑
i exp{−[(x− xi)2+(y− yi)2]/(2σ2)}, where the location of virus i in the reduced
space is (xi, yi), and σ is the standard deviation. In this way, a smooth estimation of
the underlying distribution of virus sequences from which the sequences deposited in
GenBank are collected is generated.
There are three criteria by which a new cluster can be judged to determine if it will
dominate in the human population in a future season. First, the cluster must be evident
in a density estimation. Second, the cluster must be growing. That is, there must be
evident selection pressure on the cluster. Third, the cluster must be sufficiently far from
the current vaccine strain, as judged by pepitope, for the vaccine to provide little or no
protection against the new strains. From prior work [11] and from the results discussed
below, peaks separated by more than roughly pepitope = 0.19 are sufficiently separated
that protection against the virus at one peak is expected to provide little protection
against the viruses at the other.
Results and Discussion
Vaccine Effectiveness Correlates with Antigenic Distance
Figure 2 shows how vaccine effectiveness decreases with antigenic distance. The equa-
tion for the average effectiveness (the solid line in Figure 2) is E = −2.417pepitope +
0.466.
Vaccine effectiveness declines to zero at approximately pepitope > 0.19, on aver-
age. When the dominant epitope is A or B, in which there are 19 or 21 amino acids
respectively, this means that vaccine effectiveness declines to zero after roughly 4 sub-
stitutions. When the dominant epitope is C, in which there are 27 amino acids, the
vaccine effectiveness declines to zero after roughly 5 substitutions.
Figure 2 shows that H3N2 vaccine effectiveness in humans correlates well with the
pepitope measure of antigenic distance. In particular, the Pearson correlation coefficient
of pepitope with H3N2 vaccine effectiveness in humans is R2 = 0.75. Interestingly,
this correlation is nearly the same as that previously reported for the 1971–2004 subset
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of years [11], despite the addition of 50% more data. Also of significance to note is
that these correlations with pepitope are significantly larger than those of ferret-derived
distances with vaccine effectiveness in humans, which as we will show are R2 = 0.39
or R2 = 0.37 for the two most common measures.
Consistency of Epitopic Sites
Analysis of HA1 sites shows that of the sites under diversifying selection [14] shows,
there are only 10 that by this measure should be added to the 130 known epitope sites
[11]. Alternatively, of the sites under diversifying selection, 81% are within the known
epitope regions [14]. The 130 epitope sites that we have used nearly cover the surface of
the head region of the HA1 protein, and this is why they are nearly complete. Another
recent study [34] identified epitopes somewhat different from those that we use and
further suggested that proximity to receptor binding site is a significant determinant of
H3 evolution. This result is known to be true because the sialic acid receptor binding
site is in epitope B, which is adjacent to epitope A, and epitopes A and B are the most
commonly dominant epitopes over the years (Table 1, and Table 1 of [11]). We note,
however, that upon computing the correlation of the four epitope sites defined in [34]
with the vaccine effectiveness in human data considered here one finds R2 = 0.53.
This result is to be compared to the R2 = 0.75 illustrated in Figure 2.
The Influenza A/H3N2 2014/2015 Season
The 2014/2015 influenza vaccine contains an A/Texas/50/2012(H3N2)-like virus to
protect against A/H3N2 viruses [20]. Novel viral strains detected in the human popula-
tion this year include A/Washington/18/2013, A/California/02/2014, A/Nebraska/4/2014,
and A/Switzerland/9715293/2013 [33]. It should be noted that A/California/02/2014
and A/Switzerland/9715293/2013 are completely identical in the HA1 sequence that
contains the HA epitopes [21]. Table 2 shows the pepitope values between the vac-
cine strain and these newly-emerged strains. The values indicate, along with Figure
2, that the vaccine is unlikely to provide much protection against these strains, since
pepitope > 0.19.
Dynamics of Influenza Evolution
The strains detected in 2013 and 2014 cluster in sequence space. While the strains
are sparse in the full, high-dimensional sequence space, this clustering is detected
by multidimensional scaling to the two most informative dimensions, as shown in
Figure 3. The novel strain A/Washington/18/2013 emerged in 2013, followed by
A/California/02/2014 and A/Nebraska/4/2014 in 2014, as shown in Figure 3. The later
two are sufficiently distinct from previous vaccine strains that expected vaccine effec-
tiveness is limited.
Figure 4 is an estimate of the density distribution of the influenza H3N2 HA1 se-
quences in years 2013 and 2014 in the low-dimensional space provided by the multi-
dimensional scaling. Dimensional reduction was applied to the subset of sequences in
each subfigure 4 a, b, or c. Then, Gaussian kernel density estimation was applied to
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estimate the distribution of sequences in the reduced two dimensions. Each sequence
is represented by a Gaussian function with a standard deviation of one-half substitution
in the dominant epitope.
By the criteria above, A/California/02/2014(H3N2) represented the dominant strain
circulating in the human population in 2014/2015. The time evolution in Figure 3, or
a comparison of Figure 4a with Figure 4b, shows that the A/California/02/2014 clus-
ter emerged in 2014. Table 2 shows that the distance of this new cluster from the
A/Texas/50/2012(egg) strain is pepitope > 0.19, and so from Figure 2 the expected
effectiveness of A/Texas/50/2012(egg) against these novel A/California/02/2014-like
strains is zero. Conversely, an effective vaccine for this cluster in the 2014/2015 flu sea-
son could be A/California/02/2014, or the A/Switzerland/9715293/2013 that is identi-
cal in the HA1 region.
Early detection of new dominant strains
Surprisingly, when we enlarge the region of sequence space considered, going from
Figure 4b to Figure 3 or Figure 4c, we find another large and growing peak at a dis-
tance pepitope = 0.24 from the A/Texas/50/2012 sequence. This new cluster contains
the A/Nebraska/4/2014 sequence. The A/Nebraska/4/2014 sequence is pepitope = 0.16
from the A/California/02/2014 sequence. The A/Nebraska/4/2014 sequence appears
to be dominating the A/California/02/2014 sequence in the 2015/2016 season. The
consensus strain of this cluster to which A/Nebraska/4/2014 belongs is A/New Mex-
ico/11/2014. The consensus strain minimizes the distance from all strains in the cluster,
thus maximizing expected vaccine effectiveness. Thus, A/New Mexico/11/2014 might
be a more effective choice of vaccine for the majority of the population in comparison
to A/Switzerland/9715293/2013 or A/California/02/2014.
Phylogenetic Analysis
A systematic phylogenetic analysis of recent A/H3N2 virus HA nucleotide sequences
has been carried out [35,36]. Briefly, phylogenetic trees were reconstructed from three
reference sequence datasets using the maximum likelihood method [35], with bootstrap
analyses of 500 replicates. Dominant branches of the tree were identified with distinct
clade labels. Analysis of the HA protein sequences showed that there were relatively
few residue changes across all HA clades. The 2014 vaccine strain A/Texas/50/2012
falls into clade 3C.1, while the new emerging A/California/02/2014 strain falls into
subclade 3C.3a. The A/Nebraska/4/2014 and the consensus A/New Mexico/11/2014
strains fall into subclade 3C.2a. The phylogenetic analysis indicates a closer relation-
ship of A/Nebraska/4/2014 or A/New Mexico/11/2014 to A/California/02/2014 than to
A/Texas/50/2012.
Note that phylogenetic methods make a number of assumptions. For example,
substitution rates at different sites are assumed to be the same and constant in time.
Due to selection, however, substitution rates are dramatically higher, at least 100x, in
dominant epitope regions than in non-dominant epitope or stalk regions. Multi-gene
phylogenetic methods are inconsistent in the presence reassortment, and single-gene
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phylogenetic methods are inconsistent in the presence of recombination, with the for-
mer being perhaps more significant than the latter in the case of influenza. Multidi-
mensional scaling, on the other hand, does not make either of these assumptions. MDS
also naturally filters out neutral substitutions that are random as the dominant dimen-
sions are identified. Thus, MDS provides a complementary approach to the traditional
phylogenetic analysis.
Ferret HI Analysis
Since an analysis showing the correlations between the two standard methods of an-
alyzing ferret hemagglutinin inhibition antisera assays with vaccine effectiveness in
humans in the years 1968–2004 were R2 = 0.47 and R2 = 0.57 [11], a number of
studies have appear supporting these low correlations. For example, Table 3 of [37]
shows that correlation of various immunogenicity parameters is higher with genetic
distance than with HI measures of antigenic distance. The study by Xie et. al further
illustrated the limitations of relying on ferret HI data alone [38]. We have updated
our calculation of the orrelations between the two standard methods of analyzing ferret
hemagglutinin inhibition antisera assays with vaccine effectiveness in humans to the
years 1968–2015, see [11] and the last two columns of Table 1. The correlations with
d1 and d2 are now R2 = 0.39 and R2 = 0.37, respectively, showing that ferret HI
studies have become even less correlated with human vaccine effectiveness in recent
years.
Conclusion
In conclusion, we have shown how vaccine effectiveness can be predicted using pepitope
values. This method requires only sequence data, unlike traditional methods that re-
quire animal model data, such as ferret HI assay experiments or post-hoc observations
in humans. Interestingly, the correlation of pepitope with H3N2 vaccine effectiveness
in humans isR2 = 0.75, nearly the same as that previously reported for the 1971–2004
subset of years [11], despite the addition of 50% more data. Significantly, the correla-
tion of H3N2 vaccine effectiveness in humans with pepitope is significantly larger than
with ferret-derived distances, which are R2 = 0.43 or R2 = 0.57 for the two most
common measures [11]. As an application, we estimated the effectiveness of the H3N2
vaccine strain of A/Texas/50/2012 against the observed A/California/02/2014 strains.
Clustering of the 2013 and 2014 sequence data confirms the significance of the
pepitope measure. We showed from data through 2014 that there is a transition under-
way from the A/California/02/2014 cluster to a A/New Mexico/11/2014 cluster. The
consensus sequence of A/New Mexico/11/2014 from this cluster could have been con-
sidered in late Winter 2015 for inclusion among the H3N2 candidate vaccine strains
for the 2015/2016 flu season.
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Table 2: The pepitope distances between the vaccine strain A/Texas/50/2012(egg) and
selected novel strains.
pi for each epitope i
Strain name Collection date A B C D E pepitope predicted effectiveness
A/Texas/50/2012(cell) 2012-04-15 0 0.0476 0 0.0244 0 0.0476 35%
A/Washington/18/2013 2013-11-29 0.1053 0.1905 0 0.0244 0 0.1905 0%
A/California/02/2014 2014-01-16 0.1579 0.1905 0 0.0244 0 0.1905 0%
A/Nebraska/04/2014 2014-03-11 0.1053 0.2381 0.0370 0.0244 0.0455 0.2381 0%
The pepitope distances between the vaccine strain A/Texas/50/2012(egg) and reported
novel strains [33] in 2013 and 2014. The pi values for each epitope (i = A–E), the
number of substitutions in epitope i divided by the number of amino acids in epitope
i, are also shown. The value of pepitope is the largest of the pi values, and the corre-
sponding epitope i is dominant. Zero values indicate no substitutions in that epitope.
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Figure 1: Shown is the structure of hemagglutinin in H3N2 (accession number 4O5N).
The five epitope regions [11] are color coded: epitope A is red (19 amino acids), B is
yellow (21 aa), C is orange (27 aa), D is blue (41 aa), and E is green (22 aa). Note
epitope B was dominant in 2013/2014 and 2014/2015.
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Figure 2: Vaccine effectiveness in humans as a function of the pepitope antigenic dis-
tance. Vaccine effectiveness values from epidemiological studies of healthy adults,
aged approximately 18–65, are shown (triangles). Also shown is a linear fit to the data
(solid, R2 = 0.75). Vaccine effectiveness declines to zero at pepitope = 0.19 on aver-
age. The error bars show the standard estimate of the mean of each sample point, as
discussed in the text.
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Figure 3: Dimensional reduction of all H3N2 influenza sequences collected from hu-
mans in 2013 and 2014 and deposited in GenBank. Distances are normalized by the
length of the HA1 sequence, 327 aa. Dimensional reduction identifies the principal ob-
served substitutions, i.e. those correlated with fitness of the virus, which we expect to
be in the epitope regions. A value of pepitope = 0.19 corresponds to a distance of 0.012
here. Sequences from Table 2 are labeled. While the A/Texas/50/2012 sequence was
collected in 2012, substantially similar strains were collected in 2013 and downloaded
from GenBank.
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Figure 4: Gaussian density estimation of sequences in reduced two dimensions for a) all
2013 H3N2 influenza sequences in humans, b) those 2014 H3N2 influenza sequences in
humans near the A/Texas/50/2012 sequence, and c) all 2014 H3N2 influenza sequences
in humans. The consensus strain of the cluster to which A/Nebraska/4/2014 belongs is
A/New Mexico/11/2014.
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